

Gemini Stock Analysis Report

Based on the attached "Stock Detailed Analysis Report" for **ZYDUSLIFE.NS** (generated 2026-01-24), here is the positional trading analysis.

Step 1: Audit the Data

- **Data Present:**
 - Multi-timeframe price charts (Weekly, Daily, 15-min).
 - Moving Averages (EMA 20, 50, 200).
 - Momentum Indicators (RSI, MACD).
 - Trend Indicators (Supertrend, Bollinger Bands).
 - Relative Strength (RS) Analysis vs. Sector.
 - Volume Analysis and Fundamental Snapshots.
- **Data Missing:**
 - Specific delivery percentage data (to confirm accumulation vs. churn).
 - Option Chain data (to identify Open Interest resistance levels).
- **Confidence Level: High.** The report provides a comprehensive technical suite sufficient for intermediate-term trend analysis.
 - *Note: The report date is January 2026. This analysis treats the data as current per the document's timeframe.*

Step 2: Analyze the Setup

- **Trend Structure (Bearish):** The stock is in a confirmed **Strong Downtrend**.
 - Price (882.00) is below all key EMAs ($20 < 50 < 200$). The 200 EMA (944.76) is sloping downward, acting as a major dynamic resistance "ceiling."
 - The Supertrend is signaling **SELL** with resistance at 920.17.
 - The Multi-Timeframe analysis (Page 20) confirms a **"Downtrend"** across Weekly, Daily, and 15-min intervals.
- **Momentum (Weak):**
 - **RSI:** Currently at 40.10. It is in a bearish zone (below 50) but not yet deeply oversold (below 30), suggesting there is still room for downside movement.
 - **MACD:** The histogram is negative, and the Signal Line is above the MACD Line (**Bearish**).
 - **Relative Strength:** The stock has an RS Score of 47.5/100 and is classified as "Underperforming" the Pharma sector (Page 5).
- **Volatility Signals:**
 - A **Bearish Breakout** from a volatility squeeze was identified on 2026-01-09 (Page 14). This usually initiates a sustained move in the direction of the breakout (downward).
 - Recent "Distribution Days" (Page 18) indicate institutional selling pressure in January 2026.

Step 3: Formulate the Recommendation

Should you enter this stock now? NO.

Reasoning: The stock is trying to catch a falling knife. Buying now fights the dominant trend, weak momentum, and overhead supply. There is no confluence of indicators suggesting a bottom is in place yet. The probability of a 5-15% upside is low until the market structure changes.

Conditional Plan (Reversal Setup): To consider a long position, the stock must prove that the downtrend is

Gemini Stock Analysis Report

exhausted by reclaiming key dynamic resistance levels.

- **Condition to Buy:** The stock must close **above the Daily Supertrend (920.17)**. Ideally, a close above the **200 EMA (approx. 945)** is the safest confirmation for a positional trade, but an aggressive entry can be taken on the Supertrend reversal.
- **Entry Price:** **INR 925.00** (Wait for a daily candle close above 921 to confirm strength and clear the 50 EMA).
- **Stop Loss:** **INR 875.00** (Below the recent swing low support).
- **Take Profit:** **INR 1,015.00** (Targeting the previous breakdown structure and psychological resistance).

Risk Profile for Conditional Trade: This setup offers roughly a 1:2 Risk/Reward ratio (50 points risk vs. 90 points reward). Do not enter if the price remains below 920.

News & Analyst Targets

Here is the latest stock research and information for **Zydus Lifesciences (ZYDUSLIFE)** as of **Sunday, January 25, 2026**.

1) Latest News for ZYDUSLIFE This Week (Jan 19 - Jan 25, 2026)

The week has been eventful for Zydus Lifesciences with significant regulatory and product launch updates:

USFDA Inspection at Ankleshwar Concludes (Jan 24, 2026): The USFDA completed an inspection of the company's **Unit-2 manufacturing plant at Ankleshwar, Gujarat**, which took place from January 19 to January 23, 2026. The inspection closed with **3 observations**. Importantly, the company clarified that there were **no data integrity-related observations**, which is generally viewed as a relief by investors compared to more severe regulatory actions.

Launch of World's First Nivolumab Biosimilar (Jan 22, 2026): Zydus launched '**Tishtha**', the world's first biosimilar of the cancer immunotherapy drug *Nivolumab* (brand name Opdivo), in India.

- **Impact:** This drug is used to treat multiple types of cancers. Zydus has priced it at approximately **1/4th the cost** of the innovator drug, aiming to make critical cancer therapy more affordable and accessible.

Brokerage Upgrade on Specialty Business Outlook (Jan 20, 2026): Following the recent USFDA approval of **Zycubo** (for Menkes disease), brokerage firm **Systematix Institutional Equities** upgraded the stock to a '**Buy**' rating this week, citing strong growth catalysts in the US specialty segment.

2) Upgrade or Downgrade from Brokerages

Systematix Institutional Equities (Upgrade):

- **Action:** Upgraded to **BUY**.
- **Rationale:** The firm cites the USFDA approval of *Zycubo* (marketed by subsidiary Sentynl Therapeutics) as a key earnings driver. They believe this approval significantly improves the outlook for Zydus's US specialty business and revenue potential.

Gemini Stock Analysis Report

Macquarie (Recent Maintained):

- **Action:** Maintained **BUY** (Reported mid-January).
- **View:** Continues to see upside potential, setting a target higher than the current market price.

3) Other News Impacting ZYDUSLIFE

Menkes Disease Drug (Zycubo) Approval: Although announced just prior to this week (mid-January), the **USFDA approval of Zycubo** (copper histidinate) remains a dominant driver. It is the first and only FDA-approved treatment for Menkes disease. This is a high-value product for the company's US subsidiary, Sentynt Therapeutics, and is expected to aid profitability by FY28.

Eltrombopag Tablets Approval: The company recently received final approval from the USFDA to market **Eltrombopag Tablets** (generic for Promacta), used to treat low blood platelet counts. This opens up a significant market opportunity (estimated market size ~\$1.2 billion) and strengthens their US generic portfolio.

Positive Sentiment on Regulatory Compliance: The "clean" nature (no data integrity issues) of the recent Ankleshwar inspection reinforces confidence in Zydus's manufacturing compliance, a critical factor for Indian pharma companies exporting to the US.

4) Latest Analyst Targets & Ratings

The following table summarizes the latest available price targets from major brokerages and consensus estimates.

Brokerage / Source	Rating	Target Price (INR)	Date of Report	Notes
Systematix Inst. Equities	BUY	1,038	Jan 20, 2026	Upgraded post-Zycubo approval
Macquarie	BUY	1,110	Jan 13, 2026	Maintained positive stance
Consensus Estimate	HOLD/ACCUMULATE	1,013 - 1,041	Jan 25, 2026	Average of ~30 analysts
ICICI Securities	HOLD	~910	Prev. Report	Conservative estimates
Prabhudas Lilladhar	ACCUMULATE	~970	Prev. Report	Value pick in pharma

Disclaimer: Market data and analyst targets are dynamic. Please conduct your own due diligence before making investment decisions.


Stock Detailed Analysis Report

ZYDUSLIFE.NS

Current Price: ₹882.00

Generated: 2026-01-24 18:27

ZYDUSLIFE.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	18.68%	15.04%
Net Income	Yes	Yes	17.26%	0.28%
ROE	No	Yes	-2.93%	-10.55%
EPS	Yes	Yes	17.91%	0.86%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	2.81%	2.59%
Net Income	Yes	25.27%	4.04%
ROE	Yes	17.08%	17.08%
EPS	No	12.25%	-11.77%

ZYDUSLIFE.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Emerging Leader
RS Score:	47.5/100

:

== RS RATIOS ==:

1M RS:	1.014 [Leader]
3M RS:	0.913 [Neutral]
6M RS:	0.937 [Neutral]
1Y RS:	0.922 [Neutral]

:

== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
--------------------	---------------------


:

SIGNAL CRITERIA::


✓ Emerging RS:	1M (1.014) > 3M (0.913)
✓ Medium-term Lagging:	6M=0.937, 1Y=0.922 (≤ 1.0)
✗ Performance Improving:	Not improving

Relative Strength Analysis: ZYDUSLIFE.NS vs ^CNXPHARMA
Classification: Emerging Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



ZYDUSLIFE.NS - EMA Crossover Summary

EMA 20:	894.88
EMA 50:	915.95
EMA 200:	944.76
Trend Status:	Strong Downtrend


ZYDUSLIFE.NS EMA Crossover Analysis



ZYDUSLIFE.NS - Bollinger Bands Summary

Current Price:	882.00
Upper Band:	935.81
Middle Band (SMA 20):	898.24
Lower Band:	860.66
%B:	0.2839
Band Width:	0.0837
Status:	Lower Half
Signal:	None
Recent Signal 1:	Buy Signal at 2025-11-07 00:00:00+05:30
Recent Signal 2:	Buy Signal at 2025-12-18 00:00:00+05:30
Recent Signal 3:	Buy Signal at 2026-01-13 00:00:00+05:30


ZYDUSLIFE.NS Bollinger Bands (20, 2) Analysis



ZYDUSLIFE.NS - Supertrend Summary

Status:	DOWNTREND (Sell)
Supertrend Value:	920.17
Signal Identified On:	2025-09-26

Supertrend Analysis for ZYDUSLIFE.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




ZYDUSLIFE.NS - MACD Summary

MACD Line:	-12.19
Signal Line:	-11.22
Histogram:	-0.97
Trend:	Bearish
Momentum:	Weakening
Signal:	None

ZYDUSLIFE.NS Price






ZYDUSLIFE.NS MACD (12, 26, 9)



ZYDUSLIFE.NS - Volatility Squeeze Summary

BB Width:	0.0837
ATR:	18.0214
Total Signals:	36
Signal 1:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-06 00:00:00+05:30 (Pr
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-07 00:00:00+05:30 (Pr
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-08 00:00:00+05:30 (Pr
Signal 5:	BB Squeeze (Bearish Breakout) at 2026-01-09 00:00:00+05:30


ZYDUSLIFE.NS - Volatility Squeeze Analysis



ZYDUSLIFE.NS - RSI-Volume Summary

Current RSI:	40.10
Current Volume:	460331
Volume MA 20:	550224
Bullish Divergences:	6
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-11-21 00:00:00+05:30, Price: 924.30
Bullish Div 2:	Date: 2025-12-18 00:00:00+05:30, Price: 913.65
Bearish Div 1:	Date: 2025-07-01 00:00:00+05:30, Price: 991.15
Bearish Div 2:	Date: 2025-09-18 00:00:00+05:30, Price: 1047.85

ZYDUSLIFE.NS RSI-Volume Divergence Analysis



ZYDUSLIFE.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:

32 Signals Detected

:

2025-12-24 [-]:

Distribution Day

2025-12-30 [-]:

Distribution Day

2026-01-07 [-]:

Distribution Day



2026-01-09 [-]:

Distribution Day

2026-01-20 [-]:

Distribution Day

ZYDUSLIFE.NS - Volume Analysis




Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	941.44	882.0	2025-11-03
1 Day	DOWNTREND (Sell)	920.17	882.0	2025-09-26
15 Min	DOWNTREND (Sell)	891.41	886.0	2026-01-23

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Weakening	No Signal
1 Day	Bearish	Weakening	No Signal
15 Min	Bearish	Weakening	No Signal

ZYDUSLIFE.NS - 1 Week (Candlestick + EMAs)




ZYDUSLIFE.NS - 1 Day (Candlestick + EMAs)



ZYDUSLIFE.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - ZYDUSLIFE_main



Trendlyne Snapshot - ZYDUSLIFE_forecaster

